Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorTan, Benjamin
dc.contributor.authorKhattak, Adnan
dc.contributor.authorFelip Font, Enriqueta
dc.contributor.authorKelly, Karen
dc.contributor.authorRich, Patricia
dc.contributor.authorWang, Ding
dc.date.accessioned2022-02-21T09:47:35Z
dc.date.available2022-02-21T09:47:35Z
dc.date.issued2021-07
dc.identifier.citationTan B, Khattak A, Felip E, Kelly K, Rich P, Wang D, et al. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort. Target Oncol. 2021 Jul;16:435–446.
dc.identifier.issn1776-260X
dc.identifier.urihttps://hdl.handle.net/11351/7043
dc.descriptionAdenocarcinoma esofàgic; Bintrafusp Alfa
dc.description.sponsorshipThis trial was funded by Merck KGaA, Darmstadt, Germany, and is part of an alliance between Merck KGaA and GlaxoSmithKline. Merck KGaA provided the study drug and worked with investigators on the trial design and plan, collection and analysis of data, and interpretation of results. Funding for a professional medical writer with access to the data was provided by Merck KGaA and GlaxoSmithKline.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesTargeted Oncology;16
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectEsòfag - Malalties
dc.subjectCàncer - Tractament
dc.subjectCitocines - Immunologia
dc.subject.meshEsophageal Neoplasms
dc.subject.mesh/drug therapy
dc.subject.meshTransforming Growth Factor beta
dc.subject.mesh/administration & dosage
dc.titleBintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s11523-021-00809-2
dc.subject.decsneoplasias del esófago
dc.subject.decs/farmacoterapia
dc.subject.decsfactor de crecimiento transformador beta
dc.subject.decs/administración & dosificación
dc.relation.publishversionhttps://doi.org/10.1007/s11523-021-00809-2
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Tan B] Washington University School of Medicine, St Louis, MO, USA. [Khattak A] Fiona Stanley Hospital, Perth, WA, Australia. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain. [Kelly K] University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA. [Rich P] Cancer Treatment Centers of America, Atlanta, GA, USA. Piedmont Healthcare, Atlanta, GA, USA. [Wang D] Henry Ford Cancer Institute, Detroit, MI, USA
dc.identifier.pmid34009501
dc.identifier.wos000652087400001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple